RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer
Wainberg, Z. A., Enzinger, P. C., Qin, S., Yamaguchi, K., Wang, J., Zhou, X., Gnanasakthy, A., Taylor, K., Yusuf, A., Majer, I., Jamotte, A., & Kang, Y.-K. (2024). Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer. ESMO Gastrointestinal Oncology, 6, 100095. https://doi.org/10.1016/j.esmogo.2024.100095
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.
